For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Revolution Medicines, Inc.

USPTO Granted Patents = 35

EPO Patents = 5

Trademarks = 11

Forward Citations = 154

Loading Chart...

Loading Chart...

62 inventors (with patents filed for the assignee):

Adrian L Gill (23 out of 23 patents)

Elena S Koltun (20 out of 33 patents)

James Joseph Cregg (17 out of 17 patents)

4. Andreas Buckl (13 out of 13 patents)

5. G Leslie Burnett (11 out of 11 patents)

6. Jennifer Pitzen (10 out of 10 patents)

7. Yang Liu (10 out of 17 patents)

8. Christopher Michael Semko (10 out of 10 patents)

9. Naing N Aay (10 out of 19 patents)

10. Walter S Won (9 out of 9 patents)

11. Gert Kiss (8 out of 8 patents)

12. Kevin T Mellem (8 out of 12 patents)

13. Gregory Lawrence Verdine (7 out of 84 patents)

14. James Bradley Aggen (6 out of 6 patents)

15. Gang Wang (6 out of 6 patents)

35 patents: Sort by Forward Citations

1. 12409225 - Ras inhibitors (2025-09-09),

2. 12403196 - Ras inhibitors (2025-09-02),

3. 12384750 - Ras inhibitors (2025-08-12),

4. 12365688 - Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors (2025-07-22),

5. 12280113 - Ras inhibitors (2025-04-21),

6. 12258366 - Bicyclic heteroaryl compounds and uses thereof (2025-03-25),

7. 12252497 - Ras inhibitors (2025-03-18),

8. 12202845 - Ras inhibitors (2025-01-21),

9. 12187746 - C26-linked rapamycin analogs as mTOR inhibitors (2025-01-07),

10. 12121522 - Methods of treating cancer with an mTOR inhibitor (2024-10-22),

11. 12048749 - C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors (2024-07-30),

12. 11987590 - Compounds that participate in cooperative binding and uses thereof (2024-05-21),

13. 11952352 - Ras inhibitors (2024-04-09),

14. 11739093 - Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors (2023-08-29),

15. 11739074 - Ras inhibitors (2023-08-29),

Revolution Medicines is a clinical-stage precision oncology company developing novel drugs to inhibit elusive frontier targets within notorious oncogenic pathways. Our innovative approach combines deep understanding of cancer biology with the development of small molecules that selectively and covalently target protein kinases. By continuously advancing our pipeline, we aim to bring forth a new generation of targeted therapies to treat a wide range of cancers.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

35 Patents

#53 in Redwood City, CA

#2,240 in California

#9,420 in US

#18,609 in the World

Redwood City, CA, United States of America

Revolution Medicines, Inc.

Forward Citations = 154

62 inventors:

Adrian L Gill (23 out of 23 patents)

Elena S Koltun (20 out of 33 patents)

James Joseph Cregg (17 out of 17 patents)

4. Andreas Buckl (13 out of 13 patents)

5. G Leslie Burnett (11 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…